Netherlands-based antibody therapeutics developer Citryll completed an €18.5m ($20.9m) series A round yesterday featuring antibody developer ModiQuest and pharmaceutical company BrightGene.
The round was co-led by healthcare-focused venture capital firms BioGeneration Ventures and Seventure Partners, the latter through its Health for Life Capital II fund. It included state-backed VC fund BOM Brabant Ventures.
Founded by in 2015 ModiQuest, Citryll is advancing antibodies to inhibit neutrophil extracellular traps (NETs), extracellular fibres that can contribute to conditions such as asthma, thrombosis and autoimmune diseases.
BrightGene, ModiQuest, BOM Brabant Ventures and Curie Capital had provided the funding for the round’s first close in July 2019. The additional cash will go to advancing Citryll’s lead drug candidate, CIT-103, toward clinical trials expected to be initiated in 2021.